These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 15740536)
1. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Vassiliadis T; Nikolaidis N; Giouleme O; Tziomalos K; Grammatikos N; Patsiaoura K; Zezos P; Gkisakis D; Theodoropoulos K; Katsinelos P; Orfanou-Koumerkeridou E; Eugenidis N Aliment Pharmacol Ther; 2005 Mar; 21(5):531-7. PubMed ID: 15740536 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
3. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875 [TBL] [Abstract][Full Text] [Related]
4. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL; N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance. Ikeda F; Baba N; Takaguchi K; Kubota J; Miyoshi K; Fujioka S; Moritou Y; Takeuchi Y; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K J Med Virol; 2012 Oct; 84(10):1562-70. PubMed ID: 22930504 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. Hézode C; Chevaliez S; Bouvier-Alias M; Roudot-Thoraval F; Brillet R; Zafrani ES; Dhumeaux D; Pawlotsky JM J Hepatol; 2007 May; 46(5):791-6. PubMed ID: 17321635 [TBL] [Abstract][Full Text] [Related]
7. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. He Z; Wang J; Liu K; Huang H; Du Y; Lin Z; Cai M; Feng X Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):592-7. PubMed ID: 23069315 [TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233 [TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL; Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951 [TBL] [Abstract][Full Text] [Related]
10. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Seto WK; Liu K; Fung J; Wong DK; Yuen JC; Hung IF; Lai CL; Yuen MF Antivir Ther; 2012; 17(7):1255-62. PubMed ID: 22951420 [TBL] [Abstract][Full Text] [Related]
11. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226 [TBL] [Abstract][Full Text] [Related]
12. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906 [TBL] [Abstract][Full Text] [Related]
13. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F; Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270 [TBL] [Abstract][Full Text] [Related]
14. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B. Scotto G; Palumbo E; Fazio V; Tartaglia A; Saracino A; Angarano G New Microbiol; 2005 Jul; 28(3):193-7. PubMed ID: 16240690 [TBL] [Abstract][Full Text] [Related]
15. [A study on the treatment of chronic hepatitis B with YMDD mutation]. Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977 [TBL] [Abstract][Full Text] [Related]
16. [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. Suárez E; Gila A; Figueruela B; Chueca N; Muñoz Rueda P; Puche B; Fraga E; García F; Martín JM; Andrade RJ; Nogales C; Romero-Gómez M; Salmerón J Gastroenterol Hepatol; 2011 Feb; 34(2):69-74. PubMed ID: 21334762 [TBL] [Abstract][Full Text] [Related]
17. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441 [TBL] [Abstract][Full Text] [Related]
18. [The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B]. DING JG; SUN QF; FU RQ; WU YH; HONG L Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):387-8. PubMed ID: 19497209 [No Abstract] [Full Text] [Related]
19. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Lee YS; Suh DJ; Lim YS; Jung SW; Kim KM; Lee HC; Chung YH; Lee YS; Yoo W; Kim SO Hepatology; 2006 Jun; 43(6):1385-91. PubMed ID: 16729316 [TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL; N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]